Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
7.00
+0.06 (0.86%)
At close: Mar 9, 2026, 4:00 PM EDT
6.86
-0.14 (-2.00%)
After-hours: Mar 9, 2026, 7:16 PM EDT
Kezar Life Sciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
51.26M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MindWalk Holdings | 19.02M |
| Radiopharm Theranostics | 10.86M |
| Plus Therapeutics | 5.26M |
| Alterity Therapeutics | 4.43M |
| Nutriband | 2.28M |
KZR News
- 2 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - Business Wire
- 4 months ago - Kezar Life Sciences Reports Third Quarter 2025 Financial Results - Business Wire
- 4 months ago - Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025 - Business Wire
- 5 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives - Business Wire
- 6 months ago - Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 7 months ago - Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 8 months ago - Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis - Business Wire
- 10 months ago - Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference - Business Wire